SkinCure Oncology Secures Investment for Expanded Cancer Care
SkinCure Oncology Welcomes H.I.G. Capital Investment
SkinCure Oncology, a pioneer in providing advanced Image-Guided Superficial Radiation Therapy (Image-Guided SRT), has announced a strategic investment by H.I.G. Capital, a well-respected global alternative investment firm. This significant investment creates exciting opportunities for expansion and advancement in their treatment offerings for nonmelanoma skin cancer.
Commitment to Noninvasive Cancer Treatments
During a recent announcement, SkinCure Oncology's CEO, Kerwin Brandt, expressed pride in the investment, indicating that it highlights the transformative efforts of the team in advancing Image-Guided SRT technology. This treatment modality stands out as a leading noninvasive solution for the most common form of skin cancer across the country.
Maintaining Leadership Stability
Brandt also confirmed that the current leadership team will stay in place and retain a substantial ownership stake in the revitalized company structure. This continuity is crucial for executing their vision of enhancing patient care and supporting dermatologists in delivering exceptional treatment for skin cancer patients.
Expanding Global Recognition
With the backing of H.I.G. Capital, SkinCure Oncology is positioned to amplify its market presence and broaden public understanding of its innovative GentleCure™ brand. The investment facilitates accelerated development in technologies for diagnosing and planning treatment for nonmelanoma skin cancer, enabling a more rapid adoption of the comprehensive GentleCure Experience.
Innovative Technologies in Development
The company is actively working on three innovative, laser-based technologies pending FDA approval. GentleView™ offers sophisticated imaging through hybrid reflective confocal microscopy and photoacoustic imaging. GentleBeam™, which integrates GentleView technology, enhances treatment options in dermatology with low-level x-ray capabilities. TheaiView™ is a mobile imaging device allowing ex-vivo confocal imaging of tissue specimens to aid in precise surgical procedures.
Partnerships for Quality Care
SkinCure Oncology exemplifies a partnership-driven approach, collaborating with dedicated dermatologists and Mohs surgeons to extend cancer center-grade radiation therapy to private practices. The therapy has reached over 500 physicians nationwide, impacting the lives of more than 100,000 patients.
Expert Endorsements from H.I.G. Capital
Scott Zhu, a Managing Director at H.I.G. Capital, shared enthusiasm about the collaboration, recognizing SkinCure Oncology as a leader in innovative solutions for skin cancer management. He emphasized the growing global concern surrounding skin cancer and expressed confidence in the capabilities of Brandt and his team to enhance their success in the sector.
About SkinCure Oncology
SkinCure Oncology stands as the leading force in delivering Image-Guided Superficial Radiation Therapy (Image-Guided SRT), the most advanced non-surgical treatment for common skin cancers. With partnerships across dermatology practices, they provide patient-centered care through The GentleCure™ Experience. With a network of around 500 practice sites and extensive patient treatments, SkinCure Oncology dedicates itself to innovative care in skin cancer treatment.
About H.I.G. Capital
H.I.G. Capital is a leading global investment firm, managing $65 billion in capital. Based in major cities across the United States and maintaining a robust international presence, H.I.G. specializes in providing flexible debt and equity financing to middle market companies. Since its inception, H.I.G. has successfully invested in over 400 companies worldwide, ensuring a focus on operational value and strategic growth.
Frequently Asked Questions
What is SkinCure Oncology's primary treatment method?
SkinCure Oncology primarily specializes in Image-Guided Superficial Radiation Therapy, which is an advanced noninvasive treatment for skin cancer.
Who invested in SkinCure Oncology?
H.I.G. Capital, a leading global alternative investment firm, has invested in SkinCure Oncology to support its expansion efforts.
Will the current leadership team remain after the investment?
Yes, the existing leadership team will continue to lead the company and hold significant ownership in the recapitalized business.
What technologies is SkinCure Oncology developing?
The company is developing three innovative technologies: GentleView™, GentleBeam™, and TheaiView™, all pending FDA approval.
How many patients have been treated with Image-Guided SRT?
Over 100,000 patients have received Image-Guided SRT across more than 500 physician practices nationwide.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.